Ion channel regulation in small intestinal crypts

Rhodri J. Walters, Ph.D. Thesis. University of Cambridge, ©1993.


CONTENTS

PUBLICATIONS

DECLARATION

ABBREVIATIONS

ACKNOWLEDGEMENTS

CHAPTER 1: INTRODUCTION.

1.1. Background and objectives.

1.2. Ion transport across polarised epithelial cells.

1.3. Do distinct intestinal cell populations meditate electrolyte secretion and absorbtion.

1.4. Cl- movements and their role in intestinal secretion.

1.5. The neurohormonal and endocrine control of small intestinal secretion.

1.6. Intracellular signals regulate small intestinal transport.

1.7. Cell volume regulation in epithelia.

1.8. Microscopic and macroscopic properties of ion channels are characterised using the patch-clamp technique.

1.9. Experimental approaches.

CHAPTER 2: ISOLATION OF SMALL INTESTINAL CRYPTS.

2.1. Introduction.

2.2. Methods.

2.2.1 Animals.

2.2.2. Isolation of intact crypt epithelium.

2.2.3. Measurement of thymidine kinase specific activity as a marker for crypt enterocytes.

2.2.4. Measurement of alkaline phosphatase specific activity as a marker for villus enterocytes.

2.2.5. Estimation of protein concentrations.

2.2.6. Preparation of sections of guinea-pig small intestine.

2.2.7. Staining methods.

2.3. Results.

2.3.1. Biochemical characterisation of isolated epithelial cell populations.

2.3.2. Effects of isolation protocol upon structure of small intestinal mucosa.

2.3.3. Morphology and viability of the isolated crypts.

2.4. Discussion

CHAPTER 3: A BASOLATERAL K+ CONDUCTANCE DOMINATES THE RESTING MEMBRANE POTENTIAL OF SMALL INTESTINAL CRYPTS.

3.1. Introduction.

3.2. Methods.

3.2.1. Isolation of viable crypts suitable for patch-clamp electrophysiology.

3.2.2. Solutions.

3.2.3. Perfusion arrangements for crypt electrophysiological recordings.

3.2.4. Electrophysiological recordings.

3.2.5. Data Acquisition and Analysis.

3.3. Results.

3.3.1. Effect of ion substitution experiments upon crypt membrane potential.

3.3.2. Whole-cell currents recorded from unstimulated small intestinal crypts.

3.3.3. Effect of K+ channel blockers upon the resting membrane potential of small intestinal crypts.

3.4. Discussion

CHAPTER 4: MEMBRANE POTENTIAL AND CONDUCTANCE CHANGES EVOKED BY VIP AND CARBACHOL IN SMALL INTESTINAL CRYPTS.

4.1. Introduction.

4.2. Methods.

4.2.1. Crypt preparation.

4.2.2. Solutions.

4.3. Results.

4.3.1. Effects of carbachol upon crypt membrane potential and conductance.

4.3.2. Ca2+-dependence of the action of carbachol upon crypt membrane potential.

4.3.3. Effects of phorbol esters upon crypt membrane potential and conductance.

4.3.4. Action of vasoactive intestinal polypeptide upon crypt membrane potential and conductance.

4.3.5. Membrane conductance changes evoked by forskolin in small intestinal crypts.

4.3.6. Sensitivity of the actions of VIP and carbachol to ion channel inhibitors.

4.4. Discussion.

4.4.1. Overview.

4.4.2. Second messenger pathways mediating the response to carbachol.

4.4.3. Second messenger pathways mediating the response to VIP.

4.4.4. Evidence for the activation of K+ channels by VIP and CCH.

4.4.5. Evidence for the activation of a Cl- conductance by VIP in the small intestinal crypt.

4.4.6. Evidence for the activation of a Cl- conductance by PKC and Ca2+.

4.4.7. Evidence for the presence of a cAMP-activated Cl- conductance in the small intestinal epithelium.

4.4.8. Conclusions.

CHAPTER 5: EFFECT OF SECRETAGOGUES UPON CRYPT VOLUME.

5.1. Introduction.

5.2. Methods.

5.2.1. Crypt preparation.

5.2.2. Solutions.

5.3. Results.

5.4. Discussion.

CHAPTER 6: VARIATION IN THE SPONTANEOUS MEMBRANE POTENTIAL AND RESPONSE TO AGONISTS ALONG THE CRYPT AXIS.

6.1. Introduction.

6.2. Methods.

6.2.1. Crypt preparation.

5.2.2. Solutions.

6.3. Results.

6.3.1. Variation in zero-current reversal potentials along the crypt axis.

6.3.2. Variation of membrane potential changes in response to carbachol and forskolin along the crypt axis.

6.4. Discussion.

6.4.1. Variation in the distribution of zero-current reversal potentials along the crypt axis.

6.4.2. Variation in the response to carbachol along the crypt axis.

6.4.3. Regional variations in the response to forskolin

CHAPTER 7: REGULATORY VOLUME DECREASE IN SMALL INTESTINAL CRYPTS.

7.1. Introduction.

7.2. Methods.

7.2.1. Solutions.

7.3. Results.

7.3.1. Determination of the accuracy of the volume assay.

7.3.2. Effect of hypotonicity on crypt volume.

7.3.3. Effect of increasing extracellular K+ concentration upon crypt RVD.

7.3.4. Effect of K+ and Cl- channel blockers upon RVD.

7.3.6. Effects of cell swelling upon crypt membrane potential and conductance.

7.4. Discussion.

CHAPTER 8: SINGLE-CHANNEL RECORDINGS FROM THE CRYPT BASOLATERAL MEMBRANE.

8.1. Introduction.

8.2. Methods.

8.2.1. Solutions.

8.2.2. Electrophysiological recordings.

8.2.3. Data Acquisition and Analysis.

8.3. Results.

8.3.1. Inwardly-rectifying single channel activity of the crypt basolateral membrane.

8.3.2. Cation non-selective single channel activity in the crypt basolateral membrane.

8.3.3. Effects of carbachol upon single channel activity in the crypt basolateral membrane.

8.3.4. Single channel recordings obtained with Na+ Gluconate rich pipette solutions.

8.4. Discussion.

8.4.1. Inwardly-rectifying single channel activity.

8.4.2. Cationic non-selective single channel activity.

8.4.3. Identification of the carbachol-activated K+ conductance.

CHAPTER 9: CHARACTERISATION OF A SUB-PICOSIEMEN K+ PERMEABILITY IN THE CRYPT BASOLATERAL MEMBRANE.

9.1. Introduction.

9.2. Methods.

9.2.1. Solutions.

9.2.2. Electrophysiological recordings.

9.2.3. Data acquisition and analysis.

9.3. Results.

9.4. Discussion.

CHAPTER 10: DISCUSSION AND SUMMARY.

10.1. Discussion.

10.1.1. The evolution of small intestinal transport studies.

10.1.2. Regulation of cation-selective channels in the crypt basolateral membrane.

10.1.3. Regulation of Ca2+ mobilisation in the crypt enterocyte.

10.1.4. Membrane Cl- conductance pathways of the intestinal epithelium and their central role in the pathophysiology of diarrhoea and cystic fibrosis.

10.1.5. Proliferation, differentiation and secretion in the small intestinal crypt.

10.1.6. A possible model for small intestinal secretion.

10.1.7. Conclusions.

10.2. Summary.

REFERENCES

SUMMARY OF METHODS


APPENDICES

PUBLICATIONS:

Some of the findings herein have been published as follows:

R.J.Walters and F.V.Sepulveda. A basolateral K+ conductance modulated by carbachol dominates the membrane potential of small intestinal crypts. European Journal of Physiology, 419: pp 537-539 (1991).

J.A.O'Brien, R.J.Walters and F.V.Sepulveda. Regulatory volume decrease in small intestinal crypts is inhibited by K+ and Cl- channel blockers. Biochemica Biophysica Acta, 1070: pp 501-504 (1991).

R.J.Walters, J.A.O'Brien, M.A.Valverde and F.V.Sepulveda. Membrane conductance and cell volume changes evoked by vasoactive intestinal polypeptide and carbachol in small intestinal crypts. European Journal of Physiology, 421: pp 598-605 (1992).

J.A.O'Brien, R.J.Walters, M.A.Valverde and F.V.Sepulveda. Regulatory volume increase after hypertonicity- or VIP induced cell volume decrease in small intestinal crypts is dependent on Na+/K+/2Cl- cotransport. (European Journal of Physiology (1992, in press).


ABBREVIATIONS.

The following abbreviations were used throughout:

ACh

Acetylcholine

9-AC

Anthracene-9-carboxylic acid

ANP

Atrial Natriuretic Peptide

ATP

Adenosine 5'-triphosphate

BSA

Bovine serum albumin

[Ca2+]i

Intracellular free Ca2+ concentration

CCH

Carbachol (carbamylcholine)

cAMP

Adenosine 3',5'-cyclic monophosphate

cGMP

Guanosine 3',5'-cyclic monophosphate

CF

Cystic Fibrosis

CFTR

Cystic Fibrosis Transmembrane conductance Regulator

DAG

Diacylglycerol

DMSO

Dimethylsulphoxide

DIDS

4,4'-diisothiocyanostilbene disulphonic acid

DTT

DL-dithiothreitol

DMEM

Dulbecco's Modified Eagles Medium

EDTA

Diaminoethanetetraacetic acid

EFS

Electrical field stimulation

EGTA

Ethyleneglycol-bis-(ß-aminoethyl) ether N,N,N',N'-tetraacetic acid

Emf

Electromotive force

Ei

Equilibrium potential of ion i

Em

Zero current reversal potential

EREV

Reversal potential

FSK

Forskolin

HEPES

4-(2-hydroxyethyl)-1-piperazine-ethanesulphonic acid

5-HT

5-Hydroxytryptamine

GHK

Goldman-Hodgkin-Katz

i

Current

IP3

Inositol trisphosphate

IBMX

3-isobutyl-1-methylxanthine

Isc

Short-circuit current

IV

Current-voltage

mRNA

messenger ribonucleic acid

NPPB

5-nitro-2-(3-phenylpropylamino)-benzoic acid

NMDG

N-methyl-D-glucamine

Po

Single channel open probability

PGE2

Prostaglandin E2

PKA

Protein kinase A

PKC

Protein kinase C

PMA

Phorbol 12-myristate 13-acetate

PNPP

Para-nitrophenyl phosphate

PNP

4-(para)-nitrophenol

PBS

Phosphate buffered saline

PEI

Polyethyleneimine

SEM

Standard error of the mean

STa

Escherichia coli heat stable enterotoxin

TEA

Tetraethylammonium

TCA

Trichloroacetic acid

TRIS

Tris (hydroxymethyl) amino-methane

UTP

Uridine triphosphate

V

Voltage

Va

Apical membrane potential

Vc

Clamp potential

Vh

Holding potential

VIP

Vasoactive intestinal polypeptide


ACKNOWLEDGEMENTS.

The experimental work described in this dissertation was carried out in the Department of Cellular Physiology, at the Babraham Research Institute between October 1990 and October 1993. It has been a great honour to have worked amongst so many distinguished scientists.

I am grateful to Prof.Pancho Sepulveda for the invitation to work in his laboratory and I owe much to his supervision, inspiration and attentive deliberations. My utmost appreciation goes also to Mr.Fairey, Dr.Keith Collard, Dr.Tim Jacob and Prof.Pancho Sepulveda for teaching me to think. The enduring support of my family throughout my period of study is also gratefully acknowledged.

This research has been funded by the Cystic Fibrosis Research Trust to whom I am forever indebted for the opportunity to study. I hope that the work presented in this thesis is worthy of the trust that they have placed in me.

I wish also to thank my colleagues Drs. Miguel Valverde, Gerard Mintenig, John O'Brien and Mario Diaz for their companionship, scientific expertise and teachings which have proved invaluable. My special thanks also go to my guides Dr.Yoshinori Cho and Dr.David Sattelle for helping to find a way through,

`Have no way as way, and no limitation as limitation;

for paths lead only to other paths

and we may forget to live the journey'

Materials.

Analar grade chemicals were used throughout and unless otherwise indicated were purchased from BDH chemicals Ltd.. The following chemicals are listed in alphabetical order. Compounds not commercially available were generous gifts and are marked with an asterisk. Full addresses of suppliers are given below.

Compound

Product No.

Company

 

 

 

Acetic anhydride

A 6404

Sigma

Acetylcholine (ACh)

A 6625

Sigma

Adenosine 5'-triphosphate (ATP)

A 6144

Sigma

Anthracene-9-carboxylic acid (9-AC)

A8,940-5

Aldrich Chemical Co.

Atrial Natriuretic Peptide (rat)

A 2288

Sigma

Atropine

A 0257

Sigma

Azide (sodium salt)

S/2380

Fisons

Bicinchoninic acid (commercial kit)

23225

Pierce

Bovine Serum Albumin

B 2518

Sigma

Carbachol (carbamylcholine)

C 4382

Sigma

Dimethylsulphoxide (Hybrimax)

D 2650

Sigma

4,4'-diisothiocyanostilbene disulphonic acid (DIDS)

D 3514

Sigma

DL-dithiothreitol

D 0632

Sigma

Dowex resin

1x1-100

Sigma

Dulbeccos Modified Eagles Medium

041-01885H

Gibco BRL

Ethanol (absolute)

SIN 1170

Hayman Ltd.

Ethyleneglycol-bis-(ß-aminoethyl ether N,N,N',N'-tetraacetic acid (EGTA)

E 4378

Sigma

Diaminoethanetetra-acetic acid (EDTA, dipotassium salt)

ED2P

Sigma

Diaminoethanetetra-acetic acid (EDTA, disodium salt)

ED2SS

Sigma

Forskolin

F 6886

Sigma

4-(2-hydroxyethyl)-1-piperazine-ethanesulphonic acid (HEPES)

H 3375

Sigma

5-Hydroxytryptamine (5-HT)

H 5755

Sigma

N-methyl-D-glucamine

M 2004

Sigma

* 5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB)

-

Prof.Greger

Nystatin

N 3503

Sigma

Paraformaldehyde

P 6148

Sigma

Para-nitrophenyl phosphate (PNPP)

N 3254

Sigma

4-(para)-nitrophenol (PNP)

104-1

Sigma

Phosphate buffered saline

 

Unipath Ltd.

Potassium gluconate

G 4500

Sigma

Propidium iodide

P 4170

Sigma

Quinine Hydrochloride

Q 1125

Sigma

Sucrose

S/8600

Fisons

Tetraethylammonium Chloride

T 2265

Sigma

Thymidine

T 5018

Sigma

Trichloroacetic acid

T 4885

Sigma

Triethylamine

T 0886

Sigma

Tris (hydroxymethyl) amino-methane (TRIS)

T 1503

Sigma

Vasoactive intestinal polypeptide (porcine)

V 3628

Sigma

Addresses of suppliers:

Aldrich Chemical Co. Ltd., New Road, Gillingham, Dorset, England, SP8 4JL.

Amersham International plc, Amersham, U.K..

BDH Chemicals Ltd., Poole, England, BH12 4NN.

Fisons, FSA Laboratory Supplies, Bishop Meadow Road, Loughborough, England, LE11 0RG.

Gibco BRL, Paisley, Scotland, PA3 4EP.

Prof.R. Greger, Alberts-Ludwigs-Universitat, D-7800 Freiburg, Germany.

Hayman Ltd., 70 Eastways Industrial Park, Witham, Essex, England, CM8 3YE.

Merck, Sharp & Dohme Research Laboratories,

Pierce Europe, PO Box 1512, NL-3260 BA, Oud-Beijerland, Netherlands.

Sigma Chemical Co. Ltd., Poole, England, BH17 7TG.

Unipath Ltd., Basingstoke, Hampshire, England.

main page